Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
Recruiting · NCT05682755 · Registry updated 2023-01-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2023-01-12 | NCT05682755 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sichuan University | 55 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| West China Hospital of Sichuan University | Chengdu | China | 17 |